Distinguished in Virilizing Ovarian Tumor

Dr. Amir A. Jazaeri

Obstetrics and Gynecology | Gynecologic Oncology | Oncology
7900 Fannin St, 
Houston, TX 
Offers Telehealth
Distinguished in Virilizing Ovarian Tumor
7900 Fannin St, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amir Jazaeri is an Obstetrics and Gynecologist and a Gynecologic Oncologist in Houston, Texas. Dr. Jazaeri is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Melanoma, Endoscopy, and Oophorectomy.

His clinical research consists of co-authoring 108 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Obstetrics and Gynecology
Gynecologic Oncology
Oncology
Licenses
Obstetrics & Gynecology in VA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

MD Anderson
7900 Fannin St, Houston, TX 77054

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Enrollment Status: Completed
Publish Date: September 19, 2025
Intervention Type: Biological
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
Immunomodulation of the Tumor Microenvironment in High-Grade Serous Ovarian Cancer Patients Receiving Pembrolizumab and Lenvatinib Monotherapy and Combination Therapy
Immunomodulation of the Tumor Microenvironment in High-Grade Serous Ovarian Cancer Patients Receiving Pembrolizumab and Lenvatinib Monotherapy and Combination Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Lenvatinib, Pembrolizumab
Study Phase: Phase 2
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Aldesleukin, Cyclophosphamide, Fludarabine, Ipilimumab, Nivolumab, LN-145 Autologous Tumor-Infiltrating Lymphocytes, LN-145-S1 Autologous Tumor-Infiltrating Lymphocytes
Study Phase: Phase 2
Randomized Phase I/II Study of AVB-S6-500 in Combination With Durvalumab (MEDI4736) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Randomized Phase I/II Study of AVB-S6-500 in Combination With Durvalumab (MEDI4736) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Biological, Drug
Study Drugs: Batiraxcept, Durvalumab
Study Phase: Phase 1/Phase 2
Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Enrollment Status: Completed
Publish Date: June 08, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Biological, Other
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1
Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Enrollment Status: Terminated
Publish Date: April 17, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Autologous tumor infiltrating lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine, Interleukin-2
Study Phase: Phase 2
Phase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian Cancer
Phase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: November 07, 2024
Intervention Type: Drug, Procedure, Biological
Study Drugs: Aldesleukin, Cyclophosphamide, Utomilumab, CD8-Positive T Lymphocyte Infusion
Study Phase: Phase 1/Phase 2
Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Enrollment Status: Suspended
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drugs: GRN-300 SIK Inhibitor, Paclitaxel
Study Phase: Phase 1
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Enrollment Status: Completed
Publish Date: June 27, 2019
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Pilot Study of the Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Pilot Study of the Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Enrollment Status: Withdrawn
Publish Date: March 12, 2019
Intervention Type: Drug, Other, Biological
Study Phase: Phase 2
View 11 Less Clinical Trials

108 Total Publications

Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapy.
Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapy.
Journal: Nature
Published: September 05, 2025
Similar Doctors
Pedro T. Ramirez
Distinguished in Virilizing Ovarian Tumor
Dr. Pedro T. Ramirez
Gynecologic Oncology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Pedro T. Ramirez
Gynecologic Oncology | Oncology

Tmh Physician Associates PLLC

6550 Fannin St, Suite 901, 
Houston, TX 
 (1.4 miles away)
713-441-1026
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pedro Ramirez is a Gynecologic Oncologist and an Oncologist in Houston, Texas. Dr. Ramirez is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Endoscopy. Dr. Ramirez is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Shannon N. Westin
Obstetrics and Gynecology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Shannon N. Westin
Obstetrics and Gynecology | Oncology

MD Anderson

7900 Fannin St, 
Houston, TX 
 (0.1 miles away)
713-792-1380
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shannon Westin is an Obstetrics and Gynecologist and an Oncologist in Houston, Texas. Dr. Westin is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Intrauterine Device Insertion.

Distinguished in Virilizing Ovarian Tumor
Dr. Anil K. Sood
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Anil K. Sood
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (1.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anil Sood is a Gynecologic Oncologist and an Oncologist in Houston, Texas. Dr. Sood is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Endoscopy, and Oophorectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jazaeri's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile